Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung Cancer.

Transcript:

I am Dr. Alex Spira. I am a medical oncologist with Virginia Cancer Specialists and US Oncology. Just to talk very briefly today, we presented some data at World Lung regarding amivantamab, which is a bispecific antibody against MET and EGFR.

It already has an approval in the United States against EGFR exon 20 insertions in patients with EGFR exon 20 insertions and is being studied in other EGFR mutations as well. It was a bispecific, rationally designed to target EGFR resistance, but it's also a monoclonal antibody with activity against MET.

This part of the study they were presenting this year actually just looks at the activity in patients with exon 14 skipping. We know there are already some drugs FDA-approved. There is capmatinib and tepotinib. This study was specifically looking at the use of this drug in patients with exon 14 skipping.

What we found were some very promising results. Almost all the patients had some clinical benefit. There were no patients that immediately progressed. Again, a small patient population. Interestingly, it appeared to work both in a few naive patients, but also patients who had prior therapy with drugs such as capmatinib and tepotinib, as well as some other experimental anti-MET agents.

We are hopeful that we can take this a little bit farther in the future, hopefully develop it more in our patients with exon 14 skipping mutations. Hopefully, it will provide either an alternative to the currently-approved oral TKIs, or possibly even in the resistance setting for patients that have progressed from prior TKIs.

It is exciting to hopefully be able to offer this to our patients. The study is still ongoing, and we will hopefully be able to get more information in the future. Thanks very much.